The efficacy of sildenafil for the treatment of erectile dysfunction in male peritoneal dialysis patients

Mahon, Althea; Sidhu, Paul S.; Muir, Gordon; Macdougall, Iain C.

doi:10.1053/j.ajkd.2004.10.012

Cited by 25 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The adverse events in the two sildenafil recipients (moderate abdominal pain and sciatica; mild peripheral oedema) were not related to sildenafil treatment. Furthermore, published literature suggests that sildenafil is well tolerated in men with ED and receiving dialysis (62), chronic dialysis (63), haemodialysis (64) and peritoneal dialysis (65); across these published trials, in which a total of 86 men received sildenafil, the most common adverse events were similar in frequency, nature and severity to those observed in patients without renal impairment (i.e. headache, flushing, visual disturbances, hypertension, nasal congestion and dyspepsia).…”

Section: Resultsmentioning

confidence: 99%

Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database

Giuliano

Jackson

Montorsi

et al. 2009

International Journal of Clinical Practice

142

101

View full text Add to dashboard Cite

Summary Aim: To review special safety topics associated with sildenafil and to document the tolerability of 50‐ and 100‐mg doses, overall and by age, in men with erectile dysfunction (ED). Methods: Data were collated from 67 double‐blind placebo‐controlled (DBPC) trials (> 14,000 men) conducted by the manufacturer and from the manufacturer’s postmarketing safety database (39,277 patients). The DBPC data were stratified by dose, starting dose and age (≥ 65 and ≥ 75 years). Special safety topics included cardiovascular risk, priapism, non‐arteritic anterior ischaemic optic neuropathy (NAION), impaired renal and hepatic function, drug interactions (i.e. nitrates, cytochrome P3A4 inhibitors, other ED therapies and α‐blockers) and incorrect use. Results: Sildenafil was well tolerated at a dose of 50 or 100 mg in men with ED, overall, in those aged ≥ 65 years, and in those aged ≥ 75 years. Analyses of the databases did not reveal any causal link between sildenafil and cardiovascular events, or any new safety risks relating to cardiovascular events, priapism, NAION, hearing loss or drug interactions. In the small number of men with moderate impairment of renal function or hepatic function who were treated with sildenafil in DBPC trials, the safety profile was similar to that in men with no impairment of renal or hepatic function. Overdose with sildenafil was rare in the ED population. No new safety issues, emerging trends or adverse reactions were identified in conjunction with overdose, dependence, abuse or misuse. Conclusion: This collated review confirms generally the good tolerability and established safety profile of sildenafil 50 and 100 mg in men with ED and reveals no new safety issues.

show abstract

Section: Resultsmentioning

confidence: 99%

Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database

Giuliano

Jackson

Montorsi

et al. 2009

International Journal of Clinical Practice

142

101

View full text Add to dashboard Cite

show abstract

“… Given the complex etiologies, holistic assessment and treatment of sexual dysfunction are recommended (Grade C). Recombinant EPO therapy is guided by hemoglobin level. However, its use is recommended for ED (Grade C) and for low desire in men and women (Grade C) [66]. Sildenafil is recommended for ED during hemodialysis and peritoneal dialysis (Grade B) [61]. Although improvements cannot be guaranteed, transplant may improve ED (Grade C) [62]. Sildenafil is recommended for ED post‐transplant (Grade B ) [62]. Transplantation may improve sexual desire in men and women (Grade C) [76]. …”

Section: Sexual Dysfunction Associated With End‐stage Renal Diseasementioning

confidence: 99%

Sexual Function in Chronic Illness

Basson

Rees

Wang

et al. 2010

The Journal of Sexual Medicine

201

135

View full text Add to dashboard Cite

Introduction Direct and indirect effects of chronic disease on sexual health are frequent and complex, but guidelines for their optimal management are lacking. With improved surgical and medical treatment of the underlying disease, the numbers of men and women needing assessment and management of associated sexual dysfunction are increasing. Aim To provide recommendations/guidelines for the clinical management of sexual dysfunction within the context of chronic illness. Methods An international consultation in collaboration with the major sexual medicine associations assembled 186 multidisciplinary experts from 33 countries into 25 committees. Nine experts from four countries compiled the recommendations of sexual dysfunction in chronic illness and cancer with four focusing on neurological, renal, and psychiatric disease and lower urinary tract symptoms (LUTS). Searches were conducted using Medline, Embase, Lilacs, and Pubmed databases. Main Outcome Measures Expert opinion was based on grading of evidence-based medical literature, widespread internal committee discussion, public presentation, and debate. Results Some conclusions concerning prevalence and pathophysiology of sexual dysfunction in the context of neurological disorders, end-stage renal failure, LUTS, and psychiatric disease were made. Optimal assessment of the multiple factors affecting sexuality when one or both partners are chronically ill is outlined. Evidence-based recommendations for management are presented. Comorbid depression is frequent and independently determines prevalence of sexual dysfunction in many conditions. Conclusions There is need for more research and scientific reporting on prevalence, pathophysiology, and optimal treatment of sexual dysfunction associated with chronic illness. Screening for and managing comorbid depression is strongly recommended.

show abstract

“…ED was also classified into 5 validated severity levels, ranging from none (26–30), mild (22–25), mild to moderate (17–21), moderate (11–16), through to severe (≤10) [9]. This questionnaire has been used to assess sexual function and to evaluate treatment-related changes in the dialysis population [3, 10]. The Index of Female Sexual Function (IFSF) questionnaire was provided to the female patients.…”

Section: Methodsmentioning

confidence: 99%

Sexual Dysfunction in Peritoneal Dialysis Patients

Lai¹,

Wang

Hung³

et al. 2007

Am J Nephrol

View full text Add to dashboard Cite

Background/Aims: Sexual dysfunction in patients undergoing peritoneal dialysis (PD) is highly prevalent, but studies addressing this issue are scarce. This cross-sectional study aims to evaluate sexual dysfunction and the determinants among PD patients. Methods: All chronic PD patients in 8 PD centers were asked to complete a self-reported questionnaire – the International Index of Erectile Function (IIEF) for men and the Index of Female Sexual Function (IFSF) for women – so that sexual function could be assessed. They also answered the Beck Depression Inventory (BDI) to measure depressive symptoms. Results: Among 294 patients invited for study, 54 men (mean age 48.8 ± 10.8 years) and 45 women (mean age 43.6 ± 7.4 years) were willing to and completed the sexual function questionnaires. The median IIEF score in the men was 56.25. The prevalence of erectile dysfunction, identified by the score in erectile domain of IIEF ≤25, was 51.9%. Older age and higher fasting glucose levels were independently associated with a decreased IIEF score. In women, IFSF score (with a median 27) was significant lower than in healthy peri- or postmenopausal control women. Factors of higher BDI score, receiving automated PD, and older age independently associated with a decreased IFSF score. Conclusions: Sexual dysfunction is clinically relevant and multi-dimensional among PD patients. Gender differences exist in the attributing factors of sexual functioning. These warrant more awareness and investigation in the global health care of dialysis patients.

show abstract

The efficacy of sildenafil for the treatment of erectile dysfunction in male peritoneal dialysis patients

Cited by 25 publications

References 13 publications

Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database

Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database

Sexual Function in Chronic Illness

Sexual Dysfunction in Peritoneal Dialysis Patients

Contact Info

Product

Resources

About